Evaluation of the relationship between the IL-17A gene expression level and regulatory miRNA-9 in relation to tumor progression in patients with non-small cell lung cancer: a pilot study

Monika Migdalska-Sęk · Katarzyna Góralksa · Sławomir Jabłoński · Jacek Kordiak · Ewa Nawrot · Justyna M. Kiszalkiewicz · Dorota Pastuszak-Lewandoska · Kamila Baran · Michał Stuss · Ewa Brzeziańska-Lasota

Received: 26 June 2019 / Accepted: 24 October 2019 / Published online: 9 November 2019
© The Author(s) 2019

Abstract

A pro-inflammatory cytokine, IL-17A, is associated with increased risk of developing numerous cancers, including non-small cell lung cancer (NSCLC). IL-17A is a target gene for miR-9. This encouraged us to analyze these two genes in terms of their usefulness as prognostic markers in NSCLC. The expression levels of IL-17A gene and miR-9 was assessed in 26 NSCLC tissue samples and 26 unchanged lung tissue adjacent to lung tumors (control tissue), using qPCR. In both tissue groups, a decreased expression of IL-17A was observed in 100% of samples. Increased expression of miRNA-9 was observed in 92% of tumor samples, and in 100% of control samples. Neither statistical differences in the level of expression IL-17A depending on the patient’s age, gender, smoking status, nor histopathology of the cancer was found. Regarding the presence of nodule metastasis (‘N’ value in TNM classification), significantly lower expression level of IL-17A was observed in cN2 as compared with cN1 group. Additionally, statistically lower IL-17A expression was found in III versus II tumor stage (cAJCC classification). Significant negative correlation between both studied genes was revealed in SCC subgroup. This leads to the conclusion that miRNA-9 can regulate the expression of IL-17A as an IL-17A mRNA antagonistic mediator. Inhibition of proinflammatory action of IL-17A in correlation with tumor progression can be related to various activity of Th17 cells on cancer development according to its immunogenicity, and also may suggest suppressive role of IL-17A in tumor progression. However, because of low number of analyzed samples, further studies on the functional role of IL-17A in development and/or progression NSCLC seem warranted.

Keywords Interleukin-17A · miRNA-9 · Non-small cell lung cancer · Expression level

Introduction

Lung cancer is considered the second most common cancer in the world and the most common cause of death in oncology patients. According to the prognosis of the Ministry of Health, the prevalence of lung cancer is gradually increasing. It is estimated that in 2029 the number of new cases in Poland may exceed 32,000. The most common (as much as 85% of cases) form of lung cancer is non-small cell carcinoma (NSCLC), which includes squamous cell carcinoma (SCC), adenocarcinoma (AC) and large cell carcinoma (LCC) [1].

Standard diagnosis is based on X-ray and computed tomography imaging. Currently, more and more research concern the application of molecular techniques in the diagnosis of NSCLC, including searching for genetic
markers in material collected from patients during tissue biopsy (lungs) and the so-called liquid biopsy (plasma, sputum, blood). Molecular factors are used to assess the prognosis and determine the probability of effective therapy. The most popular markers include BRCA1, ERCC1, RRM1 and EGFR genes [1, 2].

It was observed that the development of cancer in the lungs is associated with long-term smoking by the patient and the accompanying process of chronic inflammation of the lung [2]. Numerous lymphocytes capable of secretion of many chemokines and chemotactic cytokines enter the tumor microenvironment, stimulating and sustaining the process. Continuous cytokine secretion can stimulate the growth of cancer cells, suppress their apoptosis, promote tissue invasion, and metastasis. Numerous tumor cells have receptors for chemokines and proinflammatory cytokines on the surface of the cell membrane. One of them is the CCL20/CCR6 receptor pair, which plays an important role in the immunization of the lung in the course of, among others, chronic obstructive pulmonary disease or interstitial pulmonary fibrosis, and is associated with NSCLC progression [3]. CCL20/CCR6 is a pair of receptors for IL-17A, which is a precursor for the proinflammatory IL-17 cytokine family. Within the microenvironment of the tumor IL-17A can be secreted by Th17 lymphocytes, CD8 T-lymphocytes, γδT and NK cells. The interaction of IL-17 with its receptor on the surface of fibroblasts or tumor cells stimulates the secretion of other pro-inflammatory cytokines, e.g. IL-6 and metalloproteases. Studies conducted in patients with lung cancer demonstrated that increased secretion of IL-6 is associated with poor prognosis of cancer. It is also suggested that changes in IL-17A expression levels may also be related to the advancement of NSCLC. Investigations on various cancers (such as colon, breast) reported association of IL-17A with the proliferation of cancer cells, but these mechanisms is not yet fully understood [4, 5].

Particular interest of scientists is currently associated with a class of regulatory microRNAs (miRNAs). These are short non-coding RNA chains that affect the expression of many genes [6, 7]. Numerous studies have confirmed their potential as diagnostic and/or prognostic markers of many types of cancer, including lung cancer. It is suggested that miR-9-3p may regulate expression of IL-17A, which is also associated with tumor growth. Hence, changes in the expression of miR-9-3p may indicate at the same time altered expression of the IL-17A gene, and so serve as a prognostic marker in the course of NSCLC [8, 9].

The aim of the study was to assess the levels of expression of IL-17A gene and miR-9 in patients with NSCLC in relation to the tumor characteristic (histopathological subtype, TNM and AJCC classification), and to determine whether correlation between gene IL-17A and miR-9 expression exists.

Materials and methods

Clinical characterization of patients and the NSCLC tissue samples

This study was conducted in accordance with Good Clinical Practice and the principles of the Helsinki Declaration. The protocols of this study were approved by the Bioethics Committee of the Medical University in Lodz (Resolution No. KE/745/18, 12 June 2018). All participants signed an individual consent form for participation in the study.

The study was conducted on a group of 26 (11 women and 15 men) adult patients with NSCLC, aged 51 to 81 years (mean age 66.96 ± 7.95 years). In patients, lung resection (pulmonectomy or lobectomy) was performed at the Department of Thoracic Surgery, General and Oncologic Surgery, Military Medical Academy Memorial Teaching Hospital of The Medical University of Lodz—Central Veterans’ Hospital, Lodz, Poland, between 2018 and 2019. For analysis, lung tissue samples (approximately 100 mg) were collected from primary lesion and operating margin (2 cm away from the primary lesion), as a control group (macroscopically unchanged lung tissue).

The resected primary tumors were post-operatively subjected to the histopathological analysis. NSCLC samples were classified as: squamous cell carcinoma (SCC) and adenocarcinoma (AC). The stage of cancer was established according to the TNM classification and the AJCC classification system [10]. The history of smoking was available for all patients: 25 of them were smokers or former smokers, and one patient never smoked. Patients were divided into groups depending on the members of pack-years (PY, 1 Pack Year = 20 cigarettes smoked per day for 1 year according to the NCI Dictionary of Cancer Terms) [11]. Patient demographic characteristics and features of lung cancer are shown in Table 1.

RNA isolation, qualitative and quantitative RNA assessment

Lung tissue samples were placed in fixRNA buffer (Eurx, Gdańsk, Poland), then divided into smaller parts, homogenized and frozen at −80 °C until use. Isolation of total RNA from tissue homogenates was performed using mirVana™ miRNA Isolation Kit (Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Qualitative and quantitative evaluation of the isolated RNA was performed by spectrophotometric method, measuring the
absorbance with the Eppendorf BioPhotometerTM Plus (Eppendorf, Hamburg, Germany), at 260/280 nm wavelengths. Then RNA was aliquoted and frozen at –80 °C until the real-time polymerase chain reaction (qPCR) was performed.

**Evaluation of gene/miRNA expression**

The reverse transcription (RT) reaction for gene was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA), in a volume of 20 μL. The reaction mixture contained: 10 × RT buffer, 25 × dNTP Mix (100 mM), 10 × RT Random Primers, MultiScribe™ Reverse Transcriptase (50 U/μL), 10 × RT buffer, RNase Inhibitor (20 U/μL), nuclease-free water and specific RT primers (small RNA-specific RT primers) included in individual TaqMan® MicroRNA Assays: hsa-miR-9 (AUAAGCUG UAUAACCAGAAAGU) and RNU6B (CGCAAGGATGAC ACGAAATTCGTGAAGCGTTCCATATTTTT) as endogenous control (Applied Biosystems, Carlsbad, CA). RT reaction was performed in a Personal Thermocycler (Eppendorf, Germany) in the following conditions: 30 min at 16 °C, followed by 30 min at 42 °C, then the samples were heated to 10 min at 25 °C, 120 min at 37 °C, 5 min at 85 °C and cooling at 4 °C.

The reverse transcription (RT) for miRNA was carried out using of 5 μL (10 ng) of total RNA and TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) in a volume of 15 μL. RT master mix contained: 25 × dNTP Mix (100 mM), MultiScribe™ Reverse Transcriptase (50 U/μL), 10 × RT buffer, RNase Inhibitor (20 U/μL), nuclease-free water and specific RT primers (small RNA-specific RT primers) included in individual TaqMan® MicroRNA Assays: hsa-miR-9 (AUAAGCUG UAUAACCAGAAAGU) and RNU6B (CGCAAGGATGAC ACGAAATTCGTGAAGCGTTCCATATTTTT) as endogenous control (Applied Biosystems, Carlsbad, CA). RT reaction was performed in a Personal Thermocycler (Eppendorf, Germany) in the following conditions: 30 min at 16 °C, followed by 30 min at 42 °C, then the samples were heated to

| Patients’ characteristics | Number of patients (%) |
|--------------------------|------------------------|
| Gender                   |                        |
| Women                    | 11 (42)                |
| Men                      | 15 (58)                |
| Age (years)              |                        |
| ≤ 65                     | 12 (46)                |
| > 65                     | 14 (54)                |
| Smoking history          |                        |
| ≤ 40 PYs                 | 13 (52)                |
| > 40 PYs                 | 12 (48)                |
| Former smokers           | 11 (44)                |
| Current smokers          | 14 (56)                |

| Tumors’ characteristics | Number of cases (%) |
|-------------------------|---------------------|
| Histopathological subtype |                    |
| SCC                     | 14 (54)             |
| AC                      | 12 (46)             |
| TNM classification       | cTNM                |
| Tumor size (T)           |                     |
| T1                      | 6 (23)              |
| T2                      | 16 (62)             |
| T3                      | 4 (15)              |
| Presence of metastasis (N) |                   |
| N0                      | 7 (27)              |
| N1                      | 16 (61.5)           |
| N2                      | 3 (11.5)            |
| AJCC staging             |                     |
| I                       | 7 (27)              |
| II                      | 14 (54)             |
| III                     | 5 (19)              |
| p pathological, c clinical |

| Patients’ characteristics | Number of patients (%) |
|--------------------------|------------------------|
| Gender                   |                        |
| Women                    | 11 (42)                |
| Men                      | 15 (58)                |
| Age (years)              |                        |
| ≤ 65                     | 12 (46)                |
| > 65                     | 14 (54)                |
| Smoking history          |                        |
| ≤ 40 PYs                 | 13 (52)                |
| > 40 PYs                 | 12 (48)                |
| Former smokers           | 11 (44)                |
| Current smokers          | 14 (56)                |

| Tumors’ characteristics | Number of cases (%) |
|-------------------------|---------------------|
| Histopathological subtype |                    |
| SCC                     | 14 (54)             |
| AC                      | 12 (46)             |
| TNM classification       | cTNM                |
| Tumor size (T)           |                     |
| T1                      | 6 (23)              |
| T2                      | 16 (62)             |
| T3                      | 4 (15)              |
| Presence of metastasis (N) |                   |
| N0                      | 7 (27)              |
| N1                      | 16 (61.5)           |
| N2                      | 3 (11.5)            |
| AJCC staging             |                     |
| I                       | 7 (27)              |
| II                      | 14 (54)             |
| III                     | 5 (19)              |

| Patients’ characteristics | Number of patients (%) |
|--------------------------|------------------------|
| Gender                   |                        |
| Women                    | 11 (42)                |
| Men                      | 15 (58)                |
| Age (years)              |                        |
| ≤ 65                     | 12 (46)                |
| > 65                     | 14 (54)                |
| Smoking history          |                        |
| ≤ 40 PYs                 | 13 (52)                |
| > 40 PYs                 | 12 (48)                |
| Former smokers           | 11 (44)                |
| Current smokers          | 14 (56)                |

| Tumors’ characteristics | Number of cases (%) |
|-------------------------|---------------------|
| Histopathological subtype |                    |
| SCC                     | 14 (54)             |
| AC                      | 12 (46)             |
| TNM classification       | cTNM                |
| Tumor size (T)           |                     |
| T1                      | 6 (23)              |
| T2                      | 16 (62)             |
| T3                      | 4 (15)              |
| Presence of metastasis (N) |                   |
| N0                      | 7 (27)              |
| N1                      | 16 (61.5)           |
| N2                      | 3 (11.5)            |
| AJCC staging             |                     |
| I                       | 7 (27)              |
| II                      | 14 (54)             |
| III                     | 5 (19)              |

| Patients’ characteristics | Number of patients (%) |
|--------------------------|------------------------|
| Gender                   |                        |
| Women                    | 11 (42)                |
| Men                      | 15 (58)                |
| Age (years)              |                        |
| ≤ 65                     | 12 (46)                |
| > 65                     | 14 (54)                |
| Smoking history          |                        |
| ≤ 40 PYs                 | 13 (52)                |
| > 40 PYs                 | 12 (48)                |
| Former smokers           | 11 (44)                |
| Current smokers          | 14 (56)                |

| Tumors’ characteristics | Number of cases (%) |
|-------------------------|---------------------|
| Histopathological subtype |                    |
| SCC                     | 14 (54)             |
| AC                      | 12 (46)             |
| TNM classification       | cTNM                |
| Tumor size (T)           |                     |
| T1                      | 6 (23)              |
| T2                      | 16 (62)             |
| T3                      | 4 (15)              |
| Presence of metastasis (N) |                   |
| N0                      | 7 (27)              |
| N1                      | 16 (61.5)           |
| N2                      | 3 (11.5)            |
| AJCC staging             |                     |
| I                       | 7 (27)              |
| II                      | 14 (54)             |
| III                     | 5 (19)              |
Relative gene/miRNA expression was assessed by real-time polymerase chain reaction (qPCR) using 7900HT Fast Real-Time PCR System apparatus (Applied Biosystems, Carlsbad, CA). Total reaction mixture volume of 20 μL contained: cDNA (1–100 ng), KAPA PROBE FAST qPCR Master Mix (2X) ABI Prism™ (Kapa Biosystems Ltd, London, UK), RNase-free water and 20xTaqMan® Gene Expression Assay for the following genes: IL17A (Hs00174383_m1), and ACTB (Hs99999903_m1) selected as the reference gene in the qPCR reaction. The following assays for miRNAs were selected: hsa-miR-9-3p, and RNU6B as the endogenous control. The relative expression level of the tested gene/miRNA was evaluated by delta–delta CT method (TaqMan Relative Quantification Assay software, Applied Biosystems) and presented as RQ value relative to the calibrator (commercial sample—Total RNA, Invitrogen™, USA), RQ value was considered equal to 1. The obtained results were compared in terms of the NSCLC histopathological subtype, cancer stage (TNM, AJCC), age of patients, gender and smoking history. In the case of the test samples, the increased expression was recognized when the RQ value was more than 1 and the decreased expression—when the RQ value was less than 1.

Statistical analysis

In order to check the occurrence of statistical significance between the analyzed groups, Mann–Whitney U-test and/or the Kruskal–Wallis test was used depending on the size of the groups. The Spearman rank correlation coefficient was used to measure the direction and strength of the association for individual variables. The statistical analysis was carried out using Statistica 13.1 program (StatSoft, Cracow, Poland). For all statistical analysis, the level of statistical significance was assumed at p < 0.05. The results are presented as medians.

Results

IL17A gene expression analysis

The relative expression level of IL-17A was analyzed in both lung cancer tissue (NSCLC) and in control tissue (macroscopically unchanged lung tissues adjacent to lung tumors). In both groups, for all samples (100%) a decreased level of expression of the tested gene was observed (RQ < 1) in relation to the calibrator (see Fig. 1a).

Median RQ values of IL-17A gene in NSCLC group versus control group were the following: 0.032 versus 0.068; respectively. Statistical analysis didn’t confirm significant differences in the expression level of the tested gene in NSCLC versus control tissue (p = 0.191, Mann–Whitney U-test).

Mann–Whitney U-test showed no significant correlation between RQ values of IL-17A and the demographic features of NSCLC patients, patients’ age (two age groups: ≤ 65 years and > 65 years: 0.029 vs. 0.033; p = 0.489), gender (women vs. men: 0.033 vs. 0.032; p = 0.350), smoking habit (current smokers vs. former smokers: 0.029 vs. 0.033; p = 0.366), and history of smoking evaluated as PY (≤ 40 PYs vs. > 40 PYs: 0.033 vs. 0.031; p = 0.341). In addition, an analysis was carried out in the entire group of smokers to see if there is a correlation between the expression of IL-17A and the amount of cigarettes smoked in relation to the length of the smoking (PYs). Spearman’s rank correlation revealed rho = −0.120, with no statistical significant (p = 0.338).

The relative expression level of IL-17A was analyzed depending on the histopathological features of tumor. The results are presented in Table 2.

Regarding IL-17A expression among the NSCLC histopathological subtypes: SCC vs. AC, the difference was not statistically significant (p > 0.05, Mann–Whitney U-test). The expression level of IL-17A correlated with the stage of cancer according to TNM and AJCC was analyzed according to the pathological (p) and clinical (c) evaluation using TNM and AJCC classifications. The RQ value decreased with tumor size in both pT and cT groups: pT1 versus pT2 versus pT3 and cT1 versus cT2 versus cT3, however the differences were not significant (p > 0.05, Kruskal–Wallis test). According to the presence of metastasis to the nodes (pTNM staging, ‘N’ value), it was observed that RQ value of IL-17A was highest in patient with pN1, lower in pN0 and lowest in pN2, but without statistical significance (p > 0.05, Kruskal–Wallis test). Analysis of RQ values in cN groups demonstrated higher RQ in cN1 than in cN0 or cN2 (p = 0.033, Kruskal–Wallis test). Significant differences were observed between cN1 versus cN2 group (p = 0.022, Mann–Whitney U-test). The results are shown in Fig. 2.

In the pathological evaluation of tumor stages (pAJCC classification), the median RQ value was lower in stage III, and higher in I and II stages, but without statistical significance (p > 0.05, Kruskal–Wallis test). According to the cAJCC classification, we observed the highest RQ value in group II, lower in I and the lowest in III (p = 0.043, Kruskal–Wallis test). Significant differences were demonstrated between II and III tumor stages (p = 0.006, Mann–Whitney U-test). The results are presented in Fig. 3.
**miRNA-9 expression analysis**

The relative expression level of miRNA-9 was analyzed both in lung cancer tissue (NSCLC) and in control tissue (macroscopically unchanged lung tissues adjacent to lung tumors). In NCSLC group, decreased miRNA-9 expression (RQ < 1) was observed in 1/26 (4%) of the tested samples, in 1/26 (4%) the expression profile was unchanged (RQ = 1), whereas in 24/26 (92%) of samples the expression was increased (RQ > 1). In the control tissue, in all samples (100%) the increased expression level of analyzed miRNA was observed (RQ > 1) (see Fig. 1b). Median RQ values

---

![Graph](image_url)
of miRNA-9 in patients versus control group were: 50.321 versus 26.697; respectively. Statistical analysis didn’t reveal significant differences ($p = 0.210$, Mann–Whitney U-test).

Mann–Whitney U-test showed no significant correlation between RQ values of miRNA-9 and the demographic features of NSCLC patients, patients’ age (two
Fig. 3 Box-and-whisker plots representing IL-17A expression levels (median RQ values) in the studied groups according to cAJCC classification.

age groups: ≤ 65 years and > 65 years: 56.298 vs. 41.088; p = 0.625), gender (women vs. men: 37.744 vs. 56.210, p = 0.467), smoking habit (current smokers vs former smokers: 41.088 vs. 63.960, p = 0.891), and history of smoking evaluated as PY (≤ 40 PYs vs. > 40PYs: 133.967 vs. 27.444; p = 0.135). In addition, an analysis was carried out in the whole group of smokers to see if there is a correlation between the expression of miRNA-9 and the amount of cigarettes smoked in relation to the length of the smoking (PYs). Spearman’s rank correlation revealed rho = −0.139, with no statistical significance (p = 0.507).

The expression of miRNA-9 was analyzed in relation to the histopathological features of tumor (see Table 2). Regarding miRNA-9 expression in NSCLC histopathological subtypes: SCC vs AC, the difference was not statistically significant (p > 0.05, Mann–Whitney U-test). The level of miRNA-9 expression was analyzed in accordance with the pathological (p) and clinical (c) evaluation (TNM and AJCC classification). Median RQ values in groups according to pTNM staging were similar in pT1 and pT3, and higher in pT2, with no statistical significance (p > 0.05, Kruskal–Wallis test). In the clinical evaluation of tumor size, the highest RQ was observed in cT3 group, lower in cT1 and the lowest in cT2, without statistical significance (p > 0.05, Kruskal–Wallis test). According to the presence of nodule metastasis (pTNM staging, ‘N’ value), it was observed that RQ value was the highest in patient with pN2, lower in pN0 and the lowest in pN1, but without statistical significance (p > 0.05, Kruskal–Wallis test). Analysis of RQ values in groups according to the cN classifications showed an increase in the level of miRNA-9 expression along with lymph node involvement: N0 versus N1 versus N2, but without statistical significance (p > 0.05, Kruskal–Wallis test). In pAJCC groups, the median RQ value were similar in stage II and III, and higher in I stage, but without statistical significance (p > 0.05, Kruskal–Wallis test). Regarding cAJCC classification, we observed the highest RQ value in group III, lower in I and in II (p > 0.05, Kruskal–Wallis test).

Correlation between the expression level of IL-17A gene and miRNA-9

There were differences between expression of analyzed parameters in NSCLC and control samples. The levels of expression of IL-17A of NSCLC versus control samples were 0.032 versus 0.068, and for miRNA-9 were 50.321 versus 26.697.

The simultaneous decreased expression level of IL-17A and increased expression level of miRNA-9 were observed in 25 NSCLC samples (96%). Significant negative correlation was found between IL-17A and miR-9 expression levels in SCC subgroup (p = 0.034, rho = −0.569, Spearman’s rank correlation coefficient; power of the test is 0.543, t-test) (see Table 2). There were no other statistically significant correlations between the expression of studied IL-17A and miR-9 and analyzed parameters, such as patients’ age and gender, smoking history and tumor stage according to TNM and AJCC classifications (p > 0.05, Spearman’s rank correlation).
Discussion

IL-17A is a pro-inflammatory cytokine produced predominantly by Th17 CD4+ helper cells. At the same time, it is expressed also by CD8+ lymphocytes, neutrophils, eosinophils, macrophages and monocytes [5, 12]. The direct relationship between IL-17A and the increased risk of developing of numerous cancers, including NSCLC, has been demonstrated. On this basis it is considered as the central regulator of lung tumor growth [13]. Among other things, it promotes the migration and invasion of lung cancer cells via the NF-xB/ZEB1 signaling pathway. Gu et al. [14] have tracked this pathway in human lung cancer cell line A549 exposed to the IL-17A. Increased levels of IL-17A stimulated epithelial to mesenchymal transition of cells, promoting cancer development [14]. At the same time, IL-17A is involved in the tumor cell angiogenesis. Increased IL-17A expression correlates with increased levels of tumor microvessel density and vascular endothelial growth factor. Research conducted by Pan et al. [15] suggested stimulation of angiogenesis factors via STAT3/GIV signaling pathway. In addition, direct and indirect involvement of IL-17A in proliferation, apoptosis and immunomodulation of tumor cells as well as promotion of metastasis was found [5]. The animal model has also demonstrated the involvement of IL-17A in the formation of inflammation, which contributes to resistance to PD-1 blockade and sensitizes tumors to neutrophil depletion [16].

Numerous studies indicate the usefulness of the evaluation of IL-17A expression as a NSCLC diagnostic marker. The majority of research uses immunohistochemical methods, our research is one of the first which evaluate IL-17A expression levels with qPCR method. Li et al. [4] observed a significantly increased level of IL-17A in cancer patients (38 pg/ml) compared to healthy subjects (29 pg/ml). Research of Pan et al. [17] also showed a higher level of IL-17A in patients with NSCLC (21 pg/ml) than in control patients (11 pg/ml). The aim of our study was to determine the level of IL-17A gene expression in patients at various stages of NSCLC. The control material was macroscopically unchanged lung tissue surrounding the primary tumor obtained from the same patient. No differences were observed between IL-17A expression from tumor and control material. Similarly, the lack of statistical significance between the test and control tissue was observed by Kwiecień et al. [18]. As demonstrated by immunohistochemistry, increased expression usually refers to cancer cells, but sometimes it can occur in non-cancerous tissue, hence there may be no statistical differences in our own studies [19].

Smoking is considered as one of the risk factors for NSCLC developing. According to literature, smoking may also correlate with elevated levels of IL-17A [19]. In our study such correlation wasn’t found, similar results were also obtained by Pan et al. [17].

Both our study and studies conducted by other authors have not shown any correlation between the level of IL-17A expression and the patient’s age and gender, and the histological type of cancer [17, 19, 20].

However, a statistically significant relationship was found with the presence of metastasis according to the TNM classification. Significantly, higher levels of IL-17A expression were found in cN1 compared to cN2 group. Xu et al. [20] noted higher interleukin expression in the case of both lymph node and distant metastasis. Other researchers have also found higher IL-17A expression in patients with more advanced cancer—III and IV stage according to TNM classification than in patients with I and II tumor stage [17, 19, 20]. However, our results showed a difference in the level of IL-17A expression between II and III AJCC stages.

The available data from literature suggest the usefulness of IL-17A as not only diagnostic but also prognostic marker. The meta-analysis performed on the basis of research conducted among the Chinese population showed a correlation of the analyzed interleukin with the histological type of tumor and tumor progression according to TNM classification, as well as with overall survival of lung cancer patients [21], which also confirms the results of our research.

In recent years, particular attention has been paid to the miRNAs, which perform regulatory functions against numerous genes and participate in the activity of signaling pathways. The relationship of increased expression of miRNAs and numerous diseases, especially cancers, has been documented in many studies. Researchers suggest the possibility of using miRNAs as non-invasive diagnostic markers. In the case of lung cancer, miR-9 is considered a prognostic biomarker [8]. It is involved in the regulation and migration of cancer cells, and promotes cell growth and metastasis [9, 22, 23]. On the other hand, it was found that NSCLC cells overexpressing miR-9 may exhibit increased sensitivity to cisplatin, which is used in cancer chemotherapy [24]. It partly overlaps the study of gastric cancer, which showed that overexpression of miR-9-3p inhibits the development of this type of cancer [25].

Our results didn’t show any relation between the level of miR-9-3p expression, age and sex, smoking status of the patient, as well as the type of histological cancer and the stage of development according to the TNM and AJCC classification. However, other authors found the correlation between increased miR-9 level and the development of cancer. Xu et al. [8] revealed such a correlation with TNM grade, tumor size and presence of lymph node metastasis. Li et al. [22] observed a relationship between expression of miR-9-5p and the presence of metastasis, a significantly higher expression was observed in N1 and N2 patients according to TNM classification. In studies performed on
cell lines, the authors found stimulation of tumor cell proliferation and migration in the presence of the overexpression of miR-9-5p [22]. They also found worse prognosis in patients with a higher level of expression of miR-9-5p.

The contribution of miR-9 to the development of NSCLC and its usefulness as a diagnostic and prognostic marker are still under discussion. The molecular targets for miR-9 are still unknown. Due to the similarity of miR-9-3p sequences to the 7mer-A1 region in IL17A 3′UTR, the contribution of miR-9-3p in the regulation of IL-17A expression is suggested in TargetScanHuman 7.2. database [26]. Literature data suggested IL-17 and miR-9 are involved in the regulation of epithelial-mesenchymal transition -like transformation affecting the level of the same factors. IL-17 reduces the expression of E-cadherin and increases the level of vimentin protein [14]. In contrast, miR-9 increases the expression of E-cadherin, and decreased the level of vimentin [9]. In our study, we found a negative correlation between the expression of IL-17A and miR-9-3p, but only in patients with squamous cell carcinoma. The reduced level of IL-17A expression and the overexpression of miR-9-3p in lung cancer tissue may be associated with the miR-9 function as a negative IL-17A regulator. The lack of literature data indicates the need for further research in this area.

In conclusion, the observed significantly reduced level of IL-17A expression in a small group of patients with distant metastases (N2) and AJCC stage III suggests that the pro-inflammatory response of IL-17A is inhibited along with tumor progression, and indicate the suppressive role of IL-17A in NSCLC development. Due to the fact that the number of cases in the groups N0/N1 and AJCC I/II was sufficient for correct statistical analysis and the level of IL17A expression increased with the progression of cancer (although didn’t reach statistical significance), we do not exclude the oncogenic activity of IL17A in the course of NSCLC, more so that the literature data is controversial [14, 15, 27]. Probably, IL-17 as a pleiotropic cytokine can have a suppressive or stimulating effect on tumor growth. It has been shown that IL-17 can promote the growth of cancer cells through pro-inflammatory and proangiogenic activities [15, 27, 28]. At the same time, many data support the anti-cancer effect of Th17 lymphocytes. It seems, therefore, that Th17 cells may have various effects on the development of cancer depending on its immunogenicity, clinical advancement (different role in the early and late stages), as well as the origin of cancer and the role of inflammatory processes and angiogenesis in its pathogenesis [27]. Nevertheless, the correlation between miRNA-9 overexpression and low expression of IL-17A in SCC allows to conclude that miRNA-9 can regulate the expression of IL-17A as an IL-17A mRNA antagonistic mediator and the mechanism of this regulation may be important in development of SCC.

References

1. Dylewska M, Mikulowska M, Nowak S, Falkiewicz B (2016) Rak pluca w Polsce – perspektywa społeczna i medyczna 2016. Raport Sequence HC Partners Sp. z o.o. Instytut Zarządzania w Ochronie Zdrowia Uczelnia Lazarskiego, Warszawa [in Polish]
2. Potempa M, Jonczyk P, Zaleska-Ziob M (2014) Molekularne uwarunkowania raka pluc. Onkol Prak Klin 10(4):199–211 [in Polish]
3. Kirshberg S, Izhav A, Amir G, Dema J, Vernea F, Beider K, Shlomai Z, Walh H, Zamir G, Shapira OM, Peled A, Wald O (2011) Involvement of CCR3/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE 6(9):e24856. https://doi.org/10.1371/journal.pone.0024856
4. Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z (2012) IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 148:144–150. https://doi.org/10.1016/j.imlet.2012.10.011
5. Wu F, Xu J, Huang Q, Han J, Duan L, Fan J, Lv Z, Guo M, Hu G, Chen L, Zhang S, Tao X, Ma W, Jin Y (2016) The role of interleukin-17 in lung cancer. Med Inflam. https://doi.org/10.1155/2016/8494079
6. Choo K, Soon Y, Nguyen P, Hiew M, Huang CJ (2014) MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci 21:95
7. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. PNAS 108(9):3713–3718
8. Xu T, Liu X, Han L, Shen H, Liu L, Shu Y (2014) Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol 16(5):469–475. https://doi.org/10.1007/s12094-013-1106-1
9. Xu G, Shao G, Pan Q, Sun L, Zheng D, Li M, Li N, Shi H, Ni Y (2017) MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2. Am J Transl Res 9(2):478–488
10. American Joint Committee on Cancer Staging according to the IASLC Staging Project. 7th edition. Cancer 2010. http://cancerstaging.org/references/tools/quickreferences/documents/lungmedium.pdf. Accessed 30 Jan 2019
11. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed 30 Jan 2019

12. Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183(7):4169–4175. https://doi.org/10.4049/jimmunol.0901017

13. Reppert S, Koch S, Finotto S (2012) IL-17A is a central regulator of lung tumor growth. Oncoimmunology 1(5):783–785. https://doi.org/10.4161/onci.19735

14. Gu K, Li M-M, Shen J, Liu F, Cao J-Y, Jin S, Yu Y (2015) Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer Res 5(3):1169–1179

15. Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin S, Cao S, Che D, Liu F, Yu Y (2015) Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep 5:16053. https://doi.org/10.1038/srep16053

16. Akbay EA, Koyama S, Liu Y, Dries R, Bufl LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, Kulkarni M, Carretero J, Wang X, Warner-Hatten T, Osa A, Kumanogoh A, Freeman GJ, Awad MM, Christiansen DC, Bueno R, Hammerman PS, Dranoff G, Kong KK (2017) Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol 12(8):1268–1279. https://doi.org/10.1016/j.jtho.2017.04.017

17. Pan B, Che D, Cao J, Shen J, Jin S, Zhou Y, Liu F, Gu K, Man Y, Shang L, Yu Y (2015) Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer. Biomarkers 20(4):232–239. https://doi.org/10.3109/1354750X.2015.1068853

18. Kwiecien I, Stelmaszczczyk-Emmel A, Polubicz-Kownacka M, Dziedzic D, Domagala-Kulawik J (2017) Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans. Cancer Immunol Immunother 66(2):161–170. https://doi.org/10.1007/s00262-016-1930-6

19. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z (2010) Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69(3):348–354. https://doi.org/10.1016/j.lungcan.2009.11.013

20. Xu C, Hao K, Yu L, Zhang X (2014) Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer. Biomarkers 19(4):287–290. https://doi.org/10.3109/1354750X.2014.908954

21. Wang XF, Zhu YT, Wang JJ, Zeng DX, Mu CY, Chen YB, Lei W, Zhu YH, Huang JA (2017) The prognostic value of interleukin-17 in lung cancer: a systematic review with meta-analysis based on Chinese patients. PloS ONE 12(9):e0185168. https://doi.org/10.1371/journal.pone.0185168

22. Li G, Wu F, Yang H, Deng X, Yuan Y (2017) MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFB2. Biomed Pharmacother 96:1170–1178. https://doi.org/10.1016/j.biopha.2017.11.105

23. Han L, Wang W, Ding W, Zhang L (2017) MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7. J Cell Mol Med 21(9):2000–2008. https://doi.org/10.1111/jcmm.13120

24. Pan Q, Sun L, Zheng D, Li N, Shi H, Song J, Shao G (2018) MicroRNA-9 enhanced cisplatin sensitivity in nonsmall cell lung cancer cells by regulating eukaryotic translation initiation factor 5A2. Biomed Res Int. https://doi.org/10.1155/2018/1769040

25. Meng Q, Xiang L, Fu J, Chu X, Wang C, Yan B (2017) Transcriptome profiling reveals miR-9-5p as a novel tumor suppressor in gastric cancer. Oncotarget 8(23):37321–37331. https://doi.org/10.18632/oncotarget.16310

26. Agarwal V, Bell GW, Nam J-W, Bartel DP (2015) Predicting effective microRNA target sites in mammalian mRNAs. Elife 4:e05005. https://doi.org/10.7554/eLife.05005

27. Hus I, Maciag E, Rolinski J (2010) The role of Th17 cells in anticancer immunity. Postepy Hig Med Dosw 64:244–250 [in Polish]

28. Domagala-Kulawik J, Osińska I (2014) Immune alterations in lung cancer—the new therapeutic approach. Pneumonol Alergol Pol 82:286–299 [in Polish]

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.